Immune cell training may lead to new cancer therapies

NCT ID NCT05280379

Completed Knowledge-focused Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined how immune cells (myeloid cells and their bone marrow progenitors) change in patients with newly diagnosed thyroid or colon cancer. Researchers measured inflammatory markers before and after exposing cells to agents that could 'train' them to fight tumors. The goal was to better understand cancer-related inflammation and identify potential targets for future immunotherapies. No treatment was given to participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new immunotherapy approaches for cancers that don't respond to current treatments.
What could go wrong: This is a small, completed observational study with only 33 participants. It does not test any treatment, so any future therapies are highly uncertain and many years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm familial nonmedullary thyroid carcinoma Thyroid Cancer, Papillary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CARCINOMA THYROID CANCER, NONMEDULLARY

Contacts and locations

Locations

RadboudUMC

Nijmegen, Gelderland, 6525GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.